Primary tabs
Publications
Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2+ myeloid cells into the tumor microenvironment in a redundant manner
Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
Clinical Cancer Research
2023
Cellular Cancer Immunotherapy Development and Manufacturing in the Clinic
Clinical Cancer Research
2023
The current landscape of immunotherapy for pediatric brain tumors.
Nature cancer
2022
Effects of immune checkpoint blockade on antigen-specific CD8+ T cells for use in adoptive cellular therapy.
Microbiology and immunology
2022
Contemporary RNA Therapeutics for Glioblastoma.
Neuromolecular medicine
2022
CAR T Cell Locomotion in Solid Tumor Microenvironment.
Cells
2022
Vaccine Therapies for Cancer: Then and Now.
Targeted oncology
2021
Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank.
Neuro-oncology
2021
Tracking adoptive T cell immunotherapy using magnetic particle imaging.
Nanotheranostics
2021
Precision therapeutic targets for COVID-19.
Virology journal
2021
Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial.
Pediatric blood & cancer
2021
Optimizing T Cell-Based Therapy for Glioblastoma.
Frontiers in immunology
2021
Nanoparticles as immunomodulators and translational agents in brain tumors.
Journal of neuro-oncology
2021
Metabolomics Monitoring of Treatment Response to Brain Tumor Immunotherapy.
Frontiers in oncology
2021
Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate.
Veterinary immunology and immunopathology
2021
Adult precision medicine: learning from the past to enhance the future.
Neuro-oncology advances
2021
A vaccine for glioma.
Nature cancer
2021
Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity.
Nature communications
2020
RNA-electroporated T cells for cancer immunotherapy.
Oncoimmunology
2020
Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma
Clinical Cancer Research
2020
Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas
Clinical Cancer Research
2020
Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma
Cancer Research
2020
CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Proceedings of the National Academy of Sciences of the United States of America
2020
Adult immuno-oncology: using past failures to inform the future.
Neuro-oncology
2020
UNLOCKING CANCER IMMUNOTHERAPY AGAINST PEDIATRIC BRAIN TUMORS WITH TRANSCRIPTOME LOADED NANOPARTICLES: IMMU-08
Neuro-Oncology
2019
The role of CMV in glioblastoma and implications for immunotherapeutic strategies.
Oncoimmunology
2019
TMOD-07. IN SITU MICROSCOPY OF DRUG AND IMMUNE CELL INTERACTIONS AGAINST BIOFABRICATED TUMOR MODELS
Neuro-Oncology
2019
TMIC-50. 3D QUANTIFICATION OF DYNAMIC CYTOKINE GRADIENTS PRODUCED BY PRIMARY TUMOR MODELS
Neuro-Oncology
2019
TMIC-49. ABROGATING CD70 EXPRESSION IN GBM RESULTS IN A REDUCED IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT
Neuro-Oncology
2019
TMIC-29. METABOLIC INTERACTIONS BETWEEN TREATMENT-RESISTANT SLOW-CYCLING CELLS AND THE IMMUNE SYSTEM IN HIGH-GRADE GLIOMA
Neuro-Oncology
2019
TMIC-08. IDENTIFICATION OF TUMOR SPECIFIC LYMPHOCYTES IN A MURINE GLIOMA MODEL
Neuro-Oncology
2019
Sarcosine promotes trafficking of dendritic cells to draining lymph nodes and improves efficacy of a vaccine strategy for the treatment of brain tumors via CX3CL1
2019
Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling.
Journal for immunotherapy of cancer
2019
RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors.
Molecular therapy : the journal of the American Society of Gene Therapy
2019
Quantitative characterization of 3D bioprinted structural elements under cell generated forces.
Nature communications
2019
Overcoming glioma immunoediting and MHC class I loss during adoptive cellular therapy
Cancer Research
2019
Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Neuro-oncology
2019
Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy
Science Advances
2019
IMMUNOLOGIC TARGETING OF DIPG WITH H3K27M ENCODING RNA-NANOPARTICLES: IMMU-07.
Neuro-Oncology
2019
IMMU-47. RNA-NANOPARTICLE VACCINES ARE SAFE AND IMMUNOLOGICALLY ACTIVE IN CLIENT-OWNED CANINES WITH TERMINAL GLIOMAS
Neuro-Oncology
2019
IMMU-41. RNA-MODIFIED T CELLS AS PROFESSIONAL ANTIGEN PRESENTING CELLS
Neuro-Oncology
2019
IMMU-39. RNA LOADED LIPID-NANOPARTICLES FUNCTION AS CUSTOMIZABLE IMMUNOTHERAPEUTIC VEHICLES AGAINST MALIGNANT GLIOMAS
Neuro-Oncology
2019
IMMU-32. RNA-NANOPARTICLE VACCINES MEDIATE T CELL TRAFFICKING NECESSARY FOR BBB PASSAGE AND ANTI-GLIOMA IMMUNE RESPONSE
Neuro-Oncology
2019
IMMU-26. RADIATION AND TEMOZOLOMIDE UP-REGULATES CD70 EXPRESSION AND ENHANCES CAR T-CELL RECOGNITION IN GBM
Neuro-Oncology
2019
IMMU-25. MAGNETIC PARTICLE IMAGING FOR NON-INVASIVE TRACKING OF ADOPTIVE CELL TRANSFER IN CANCER IMMUNOTHERAPY
Neuro-Oncology
2019
IMMU-24. A COMPREHENSIVE IN SILICO APPROACH TO DISCOVERING TUMOR REJECTION ANTIGENS IN MALIGNANT BRAIN TUMORS
Neuro-Oncology
2019
IMMU-15. A UNIQUE SELF-STIMULATIVE PROPERTY OF CD70 CAR ADVANCES T CELL FUNCTION AND ANTI-TUMOR RESPONSE IN GLIOBLASTOMA
Neuro-Oncology
2019
IMMU-13. MECHANISMS OF IMMUNOLOGICAL ESCAPE DURING ADOPTIVE CELLULAR THERAPY IN HIGH GRADE GLIOMA
Neuro-Oncology
2019
IMMU-07. CELLULAR IMMUNOTHERAPY TO OVERCOME TEMOZOLOMIDE INDUCED T CELL EXHAUSTION IN GLIOBLASTOMA
Neuro-Oncology
2019
IMMU-05. DISRUPTION OF THE CCR2 CHEMOKINE RECEPTOR PATHWAY OVERCOMES THERAPEUTIC RESISTANCE TO PD-1 BLOCKADE IN MALIGNANT GLIOMA
Neuro-Oncology
2019
Highlights of the inaugural ten–the launch of Neuro-Oncology Advances
Neuro-Oncology Advances
2019
Emerging trends in immunotherapy for pediatric sarcomas.
Journal of hematology & oncology
2019
EXTH-15. INCREASING THE TRAFFICKING OF DENDRITIC CELLS VIA CXC CHEMOKINE SIGNALING PATHWAY LEADS TO IMPROVED ANTI-TUMOR EFFICACY OF DENDRITIC CELL VACCINES
Neuro-Oncology
2019
Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging.
ACS nano
2019
Concise Review: Modulating Cancer Immunity with Hematopoietic Stem and Progenitor Cells.
Stem cells (Dayton, Ohio)
2019
Chemotaxis of Spatially Patterned T cell Populations near 3D Printed Tumors
2019
CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors.
Nature communications
2019
BSTM-03. INCREASING ANTI-TUMOR T CELL ACTIVATION, VELOCITY, AND MIGRATION TO BRAIN STEM GLIOMA USING HEMATOPOIETIC STEM AND PROGENITOR CELLS
Neuro-Oncology
2019
Adoptive cellular therapy overcomes tumor-induced dysregulation of myelopoiesis
Cancer Research
2019
ATIM-34. SINGLE-CELL RNA SEQUENCING REVEALS DYNAMIC IMMUNE RESPONSE CHANGES IN GLIOBLASTOMA PATIENT WITH DURABLE COMPLETE RESPONSE TO CMV PP65-LAMP RNA-PULSED DENDRITIC VACCINES
Neuro-Oncology
2019
ATIM-13. MULTIMODAL IMMUNOTHERAPY WITH IO-VAC® FOR PATIENTS WITH GBM: A SINGLE INSTITUTION EXPERIENCE
Neuro-Oncology
2019
3D in vitro system for immuno-oncology: Real-time imaging of drug delivery, tumoroids, and immune cell activity
Cancer Research
2019
mRNA-nanoparticles to enhance and track dendritic cell migration
Journal of Clinical Oncology
2018
Total tumor RNA pulsed dendritic cells plus adoptive transfer of ex-vivo enriched autologous T-lymphocytes in the treatment of children with primary brain tumors
Neuroimmunology and Neuroinflammation
2018
The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas.
Frontiers in molecular neuroscience
2018
Temozolomide for immunomodulation in the treatment of glioblastoma.
Neuro-oncology
2018
TMIC-29. REPROGRAMMING BONE MARROW OF TUMOR-BEARING HOSTS FOR GLIOMA IMMUNOTHERAPY
Neuro-Oncology
2018
TMIC-29. REPROGRAMMING BONE MARROW OF TUMOR-BEARING HOSTS FOR GLIOMA IMMUNOTHERAPY
Neuro-Oncology
2018
TMIC-12. TUMOR-HOMING RNA-NANOPARTICLES REPROGRAM IMMUNE CELLS IN THE BRAIN TUMOR MICROENVIRONMENT
Neuro-Oncology
2018
THE IMPACT OF BRAIN TUMORS ON HEMATOPOIETIC STEM CELL-DERIVED T CELLS: IMMU-24
Neuro-Oncology
2018
STEM-09. CANCER STEM CELL IMMUNOEDITING
Neuro-Oncology
2018
Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy.
Nano letters
2018
PDTM-18. ACTIVATION OF TUMOR-REACTIVE T CELLS AGAINST BRAIN STEM GLIOMA USING HEMATOPOIETIC STEM CELLS
Neuro-Oncology
2018
PDCT-08. TRACKING THE T CELL REPERTOIRE AFTER ADOPTIVE CELL THERAPY IN PEDIATRIC PATIENTS WITH RECURRENT MEDULLOBLASTOMA
Neuro-Oncology
2018
MBRS-63. CCR2+ HEMATOPOIETIC STEM CELLS OVERCOME TREATMENT RESISTANCE TO PD-1 IN MEDULLOBLASTOMA
Neuro-Oncology
2018
MBRS-02. PERSONALIZED IMMUNOTHERAPY WITH TRANSLATABLE RNA NANOPARTICLES TARGETING MEDULLOBLASTOMA
Neuro-Oncology
2018
Lin-CCR2+ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade.
Nature communications
2018
Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma
The EMBO journal
2018
Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma.
The EMBO journal
2018
Immunotherapy for brain tumors
Current Treatment Options in Oncology
2018
Immunotherapy for Brain Tumors.
Current treatment options in oncology
2018
IMMU-67. PERSONALIZED TUMOR MRNA LOADED LIPID NANOPARTICLES PRIME THE SYSTEMIC AND INTRATUMORAL GBM MILIEU FOR RESPONSE TO IMMUNOTHERAPY
Neuro-Oncology
2018
IMMU-66. A NOVEL METABOLITE TO INCREASE EFFICACY OF CELLULAR IMMUNOTHERAPY IN THE TREATMENT OF GLIOBLASTOMA
Neuro-Oncology
2018
IMMU-64. A DECADE OF RESEARCH TARGETING IMMUNOSUPPRESSIVE IDO1 IN GLIOBLASTOMA: NEARING THE FINISH LINE OR JUST BEGINNING THE MARATHON?
Neuro-Oncology
2018
IMMU-56. CXCR1/2 MODIFIED CARs CO-OPT RADIATION-INDUCED IL-8 FOR ENHANCED CHEMOTAXIS OF THE CAR T CELLS AND MAXIMAL ANTI-TUMOR EFFICACY
Neuro-Oncology
2018
IMMU-45. DOSE MODULATION OF TEMOZOLOMIDE HAVE DISTINCT EFFECTS ON HOST RESPONSE TO PD-1 BLOCKADE
Neuro-Oncology
2018
IMMU-45. DOSE MODULATION OF TEMOZOLOMIDE HAVE DISTINCT EFFECTS ON HOST RESPONSE TO PD-1 BLOCKADE
Neuro-Oncology
2018
IMMU-45. DOSE MODULATION OF TEMOZOLOMIDE HAVE DISTINCT EFFECTS ON HOST RESPONSE TO PD-1 BLOCKADE
Neuro-Oncology
2018
IMMU-43. RNA-MODIFIED T CELLS AS A NON-INVASIVE AND EFFICACIOUS STRATEGY TO DELIVER THERAPEUTIC MACROMOLECULES LOCALLY TO INTRACRANIAL TUMORS
Neuro-Oncology
2018
IMMU-32. RETARGETING IMMUNOEDITED GLIOMA ESCAPE VARIANTS WITH ADOPTIVE CELLULAR THERAPY
Neuro-Oncology
2018
IMMU-27. Re-MATCH PROTOCOL: PHASE I STUDY OF AUTOLOGOUS TUMOR SPECIFIC LYMPHOCYTE TRANSFER (ALT) + DC VACCINE (DCV) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY (MAC) AND AUTOLOGOUS STEM CELL RESCUE (HDC + ASCR) OR NON-MYELOABLATIVE CHEMOTHERAPY (NMAC) IN PATIENTS WITH RECURRENT CENTRAL PNETs (r-PNET)
Neuro-Oncology
2018
IMMU-20. HEMATOPOIETIC STEM CELLS POTENTIATE EFFICACY OF ADOPTIVE CELL THERAPY AGAINST BRAIN STEM GLIOMA
Neuro-Oncology
2018
IMMU-17. HEMATOPOIETIC STEM CELL-DERIVED DENDRITIC CELLS REPROGRAM THE BRAIN TUMOR MICROENVIRONMENT
Neuro-Oncology
2018
IMMU-15. HIGH-RESOLUTION ANALYSIS OF THE T-CELL RECEPTOR REPERTOIRE AFTER ADOPTIVE CELLULAR THERAPY IN PEDIATRIC PATIENTS WITH CENTRAL PNETs (Re-MATCH TRIAL)
Neuro-Oncology
2018
IMMU-09. Outcome of patients with recurrent diffuse intrinsic pontine glioma (DIPG) treated with pembrolizumab (anti-PD-1): a Pediatric Brain Tumor Consortium study (PBTC045)
Neuro-Oncology
2018
IMMU-04. RNA-ENGINEERED T CELLS AS A BIOLOGICAL CARRIER TO DELIVER MACROMOLECULES TO INTRACRANIAL TUMORS
Neuro-Oncology
2018
EXTH-36. BIFUNCTIONAL RNA NANOPARTICLES INDUCE ANTITUMOR IMMUNE RESPONSES AND ALLOW MRI-BASED DETECTION OF DENDRITIC CELL MIGRATION AS A BIOMARKER OF ANTITUMOR IMMUNE RESPONSE
Neuro-Oncology
2018
Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.
Cancer research
2018
DRES-13. VEGF BLOCKADE ENHANCES T REGULATORY CELL FUNCTION BY DYSREGULATING GLUTAMATE TRANSPORT IN GBM
Neuro-Oncology
2018
DDIS-06. AAV TOOLKIT ENABLING PRECISION COMBINATORIAL VIROTHERAPY FOR GLIOBLASTOMA
Neuro-Oncology
2018
Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research
2018
Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes.
International journal of molecular sciences
2018
CD70, a novel target of CAR T-cell therapy for gliomas.
Neuro-oncology
2018
Analysis of immunobiologic markers in primary and recurrent glioblastoma
Journal of Neuro-Oncology
2018
2173 RNA-nanoparticles to enhance and track dendritic cell migration
Journal of Clinical and Translational Science
2018
Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM.
International journal of cancer
2017
Translational nanoparticle engineering for cancer vaccines.
Oncoimmunology
2017
The development of dendritic cell vaccine-based immunotherapies for glioblastoma.
Seminars in immunopathology
2017
The Effects of New or Worsened Postoperative Neurological Deficits on Survival of Patients With Glioblastoma
Journal of Neurosurgery
2017
The Clinical and Financial Impact of a Pediatric Surgical Neuro-Oncology Clinical Trial
Journal of Neuro-Oncology
2017
TMIC-26. IMMUNOMODULATION WITH TEMOZOLOMIDE TO IMPROVE EFFICACY OF IMMUNE CHECKPOINT INHIBITION FOR THE TREATMENT OF GLIOBLASTOMA
Neuro-Oncology
2017
TMIC-12. REPROGRAMMING THE BRAIN TUMOR MICROENVIRONMENT WITH HEMATOPOIETIC STEM AND PROGENITOR CELLS
Neuro-Oncology
2017
Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.
Oncoimmunology
2017
STEM-09. TREATMENT-RESISTANT SLOW-CYCLING CELLS SUPPORT METABOLIC HETEROGENEITY AND ADAPTABILITY IN GLIOBLASTOMA
Neuro-Oncology
2017
Regulatory T cell subsets in patients with medulloblastoma at diagnosis and during standard irradiation and chemotherapy (PBTC N-11)
Cancer Immunology Immunotherapy
2017
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses
Human Vaccines and Immunotherapeutics
2017
PDCT-12. TRACKING T-CELL IMMUNE RECONSTITUTION AFTER ADOPTIVE CELLULAR THERAPY TARGETING RECURRENT MEDULLOBLASTOMA AND PNETS USING DEEP T-CELL RECEPTOR (TCR) REPERTOIRE SEQUENCING
Neuro-Oncology
2017
Overcoming resistance to immune checkpoint blockade with RNA-loaded nanoparticles
Journal of Clinical Oncology
2017
Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.
Journal of immunology research
2017
METB-02. A SENSITIVE METABOLIC SIGNATURE TO PREDICT IMMUNE RESPONSE AFTER IMMUNOTHERAPY FOR BRAIN TUMORS
Neuro-Oncology
2017
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
Clinical cancer research : an official journal of the American Association for Cancer Research
2017
Immunotherapy for Pediatric Brain Tumors.
Brain sciences
2017
IMMU-68. REMODELING IMMUNITY AGAINST MEDULLOBLASTOMA VIA RNA-LOADED NANOPARTICLES
Neuro-Oncology
2017
IMMU-65. Lin-CCR2+ HEMATOPOIETIC STEM CELLS OVERCOME RESISTANCE TO PD-1 BLOCKADE
Neuro-Oncology
2017
IMMU-63. OVERCOMING GLIOBLASTOMA RESISTANCE TO IMMUNE CHECKPOINT BLOCKADE VIA RNA-LOADED NANOPARTICLES
Neuro-Oncology
2017
IMMU-57. STRATEGY TO ENHANCE DC MIGRATION FOR INCREASED EFFICACY OF DENDRITIC CELL VACCINE IMMUNOTHERAPY
Neuro-Oncology
2017
IMMU-31. IN VIVO CELLULAR TRACKING WITH 13C LABELING OF ADOPTIVELY TRANSFERRED T CELLS FOR THE TREATMENT OF BRAIN TUMORS
Neuro-Oncology
2017
IMMU-30. TCR Vb CLONAL EXPANSION PREDICTS RESPONSE TO ADOPTIVE IMMUNOTHERAPY AGAINST MEDULLOBLASTOMA
Neuro-Oncology
2017
IMMU-25. ENHANCED T CELLS TUMOR RECOGNITION USING DENDRITIC CELLS PULSED WITH CHIMERIC RNAs ENCODING FULL-LENGTH LAMP-1 FUSION CONSTRUCTS
Neuro-Oncology
2017
IMMU-25. ENHANCED T CELLS TUMOR RECOGNITION USING DENDRITIC CELLS PULSED WITH CHIMERIC RNAs ENCODING FULL-LENGTH LAMP-1 FUSION CONSTRUCTS
Neuro-Oncology
2017
IMMU-22. ADOPTIVE CELL THERAPY AGAINST DIPG USING DEVELOPMENTALLY REGULATED ANTIGENS
Neuro-Oncology
2017
IMMU-14. REMODELING IMMUNITY AGAINST MEDULLOBLASTOMA VIA RNA LOADED NANOPARTICLES
Neuro-Oncology
2017
IMMU-14. REMODELING IMMUNITY AGAINST MEDULLOBLASTOMA VIA RNA LOADED NANOPARTICLES
Neuro-Oncology
2017
IMMU-11. AN ANALYSIS OF IMMUNOPHENOTYPE, INCLUDING PD-L1 AND PD1 EXPRESSION, IN PEDIATRIC CNS MALIGNANCIES: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY
Neuro-Oncology
2017
DIPG-23. PHASE I STUDY OF ADOPTIVE CELLULAR THERAPY (X-ALT) PLUS TOTAL TUMOR RNA-DENDRITIC CELL VACCINE (TTRNA-DC) + HEMATOPOIETIC STEM CELLS (HSC) DURING RECOVERY FROM IRRADIATION(RT) WITH (GROUP A) OR WITHOUT (GROUP B) DOSE-INTENSIFIED TEMOZOLOMIDE (DI-TMZ) IN PATIENT (PTS) WITH NEWLY DIAGNOSED DIFFUSE BRAIN STEM GLIOMAS (DIPG) (BRAVO TRIAL)
Neuro-Oncology
2017
CD70 as a critical mediator of tumor progression and immunosuppression in gliomas
Journal of Clinical Oncology
2017
CD4+ and Perivascular Foxp3+ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression.
Frontiers in immunology
2017
Adoptive Immunotherapy Against Brain Tumors
Translational Immunotherapy of Brain Tumors
2017
A phase I trial of pomalidomide for children with recurrent, progressive/refractory central nervous system (CNS) tumors: A Pediatric Brain Tumor Consortium (PBTC) study.
Journal of Clinical Oncology
2017
2422: Magnetic nanoparticles facilitate tracking of dendritic cells for treatment of malignant brain tumors
Journal of Clinical and Translational Science
2017
Vaccine-related allergic reaction: case report
2016
Tetanus-Diphtheria Recall Responses and Chemokine CCL3 Delivery Enhance Migration and Efficacy of Dendritic Cell Vaccines
Journal Of Neurosurgery
2016
TMIC-14. TUMOR EVOLUTION OF GLIOMA INTRINSIC GENE EXPRESSION SUBTYPE ASSOCIATES WITH IMMUNOLOGICAL CHANGES IN THE MICROENVIRONMENT
Neuro-Oncology
2016
Reviewer Lists for Neuro-Oncology
Neuro-Oncology
2016
QUANTITATIVE TRACKING OF T-CELL CLONES AFTER ADOPTIVE CELLULAR THERAPY TARGETING RECURRENT MEDULLOBLASTOMA USING MASSIVELY PARALLEL RNA SEQUENCING TECHNOLOGY
Neuro-Oncology
2016
Prioritization schema for immunotherapy clinical trials in glioblastoma.
Oncoimmunology
2016
PDCT-15. Re-MATCH: A PHASE 2 MULTI-INSTITUTIONAL CLINICAL TRIAL OF ADOPTIVE CELLULAR THERAPY FOLLOWING MYELOABLATIVE OR NON-MYELOABLATIVE CHEMOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH RECURRENT MEDULLOBLASTOMA AND PNETs
Neuro-Oncology
2016
Migration of dendritic cells to the lymph nodes and its enhancement to drive anti-tumor responses
Critical Reviews In Oncology/Hematology
2016
MicroRNAs provide a novel pathway toward combinatorial immune checkpoint blockade.
Neuro-oncology
2016
MB-94 IMMUNOLOGIC PROFILE OF PATIENTS WITH NEWLY-DIAGNOSED MEDULLOBLASTOMA AT INITIAL DIAGNOSIS AND DURING STANDARD RADIATION AND CHEMOTHERAPY (PBTC-N11)
Neuro-Oncology
2016
Know your neighbors: Different tumor microenvironments have implications in immunotherapeutic targeting strategies across MB subgroups.
Oncoimmunology
2016
IMST-55. LYMPH NODE AND URINE METABOLOMICS: A NON-INVASIVE STRATEGY TO PREDICT EFFICACY OF DENDRITIC CELL VACCINE IMMUNOTHERAPY
Neuro-Oncology
2016
IMST-47. IDENTIFICATION AND EXPANSION OF GLIOMA-SPECIFIC T CELLS USING TCR Vβ EXPRESSION
Neuro-Oncology
2016
IMST-33. ENHANCED T CELL ACTIVATION USING DENDRITIC CELLS PULSED WITH CHIMERIC RNAs ENCODING FULL-LENGTH LAMP-1 FUSION CONSTRUCTS
Neuro-Oncology
2016
IMST-27. CD70–A CRITICAL MEDIATOR OF TUMOR PROGRESSION AND IMMUNOSUPPRESSION IN GLIOMAS
Neuro-Oncology
2016
IMST-16. TRANSLATABLE RNA NANOPARTICLES SUPPLANT DENDRITIC CELL VACCINES IN CELLULAR IMMUNOTHERAPY
Neuro-Oncology
2016
Gene-modified dendritic cell vaccines for cancer.
Cytotherapy
2016
Disruption of KIF3A in patient-derived glioblastoma cells: effects on ciliogenesis, hedgehog sensitivity, and tumorigenesis.
Oncotarget
2016
Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research
2016
COMBINATION OF VEGF-A AND PD-1 BLOCKADE MAY ENHANCE ANTITUMOR EFFICACY IN GBM
Neuro-Oncology
2016
CMV-targeted Dendritic Cell Vaccines Increase Survival for Randomized Patients with Glioblastoma in Successive Trials
Journal of Neurosurgery
2016
Vaccination strategies for neuro-oncology.
Neuro-oncology
2015
Tetanus toxoid conditioning enhances migration and efficacy of dendritic cell vaccines in patients with glioblastoma
2015
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
Nature
2015
Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.
Cancer immunology research
2015
Rna Nanoparticle Vaccines Facilitate and Sustain Adoptive Cellular Therapy Targeting Pediatric Intracranial Malignancies
Pediatric Blood & Cancer
2015
RNA NANOPARTICLE VACCINES FACILITATE AND SUSTAIN ADOPTIVE CELLULAR THERAPY TARGETING PEDIATRIC INTRACRANIAL MALIGNANCIES: YOUNG INVESTIGATOR AWARD WINNER# 4012
Pediatric Blood & Cancer
2015
Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.
Oncoimmunology
2015
METB-02USING MAGNETIC RESONANCE SPECTROSCOPY TO TRACK DENDRITIC CELLS FOR VACCINE IMMUNOTHERAPY
Neuro-Oncology
2015
Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma
Cancer Immunology Immunotherapy
2015
Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma.
Cancer immunology, immunotherapy : CII
2015
IMPS-42 CD70—A KEY DRIVER OF CHEMOKINE-MEDIATED IMMUNE SUPPRESSION AND INDICATOR OF NEGATIVE PROGNOSIS FOR GLIOBLASTOMA
Neuro-Oncology
2015
IMPS-36RNA NANOPARTICLE VACCINES RE-PROGRAM HOST-IMMUNITY AGAINST GLIOBLASTOMA INDUCING THERAPEUTIC ANTI-TUMOR ACTIVITY
Neuro-Oncology
2015
IMPS-25DIFFERENTIAL TUMOR MICROENVIRONMENTS AND RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN MOLECULAR SUBTYPES OF MURINE MEDULLOBLASTOMA
Neuro-Oncology
2015
IM-15ANTI-TUMOR EFFICACY OF ADOPTIVE CELLULAR THERAPY IS SIGNIFICANTLY INCREASED BY HEMATOPOIETIC STEM CELLS
Neuro-Oncology
2015
IM-14IMMUNOLOGIC TARGETING OF MEDULLOBLASTOMA SUBTYPES USING DEVELOPMENTALLY REGULATED ANTIGENS
Neuro-Oncology
2015
IM-13MOLECULAR ENGINEERING OF AMPLIFIED TUMOR RNA-PULSED DENDRITIC CELLS IN ADOPTIVE CELLULAR THERAPY TARGETING MEDULLOBLASTOMA AND GLIOBLASTOMA
Neuro-Oncology
2015
IM-12 RNA NANOPARTICLE VACCINES RE-PROGRAM HOST IMMUNITY IN FAVOR OF ENHANCED EFFECTOR RESPONSES AGAINST INTRACRANIAL MALIGNANCIES
Neuro-Oncology
2015
IM-12 RNA NANOPARTICLE VACCINES RE-PROGRAM HOST IMMUNITY IN FAVOR OF ENHANCED EFFECTOR RESPONSES AGAINST INTRACRANIAL MALIGNANCIES
Neuro-Oncology
2015
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas
Neuro-Oncology
2015
Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma.
Journal of neuro-oncology
2015
Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics.
Journal for immunotherapy of cancer
2015
Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells
Clinical Cancer Research
2014
ROBUST INDUCTION OF TYPE-1 CD8+ T-CELL RESPONSES IN WHO GRADE II LOW-GRADE GLIOMA PATIENTS RECEIVING PEPTIDE-BASED VACCINES IN COMBINATION WITH POLY-ICLC
Neuro-Oncology
2014
Memory Responses Govern Dendritic Cell Migration to Vaccine-Site Draining Lymph Nodes Resulting in Enhanced Anti-Tumor Efficacy
Journal of Surgical Research
2014
Immunological targeting of cytomegalovirus for glioblastoma therapy.
Oncoimmunology
2014
IT-35 cGMP MANUFACTURING OF EX VIVO EXPANDED TUMOR-SPECIFIC T CELLS AND AMPLIFIED TUMOR RNA-PULSED DC VACCINES TARGETING GLIOBLASTOMA AND MEDULLOBLASTOMA
Neuro-Oncology
2014
IT-31HARNESSING THE IMMUNOLOGIC CAPACITY OF THE LIVER AGAINST GLIOBLASTOMA MULTIFORME
Neuro-Oncology
2014
IT-25DEVELOPMENTALLY REGULATED ANTIGENS FOR IMMUNOLOGIC TARGETING OF MEDULLOBLASTOMA SUBTYPES
Neuro-Oncology
2014
IT-10SYNERGISTIC CELLULAR INTERACTIONS IN ADOPTIVE IMMUNOTHERAPY LEADS TO IMMUNOLOGIC REJECTION OF MALIGNANT GLIOMA
Neuro-Oncology
2014
IT-06PERSONALIZED IMMUNOTHERAPY FOR THE TREATMENT OF GLIOBLASTOMA
Neuro-Oncology
2014
GE-11THE FLORIDA CENTER FOR BRAIN TUMOR RESEARCH (FCBTR): BUILDING INFRASTRUCTURE TO FIND A CURE
Neuro-Oncology
2014
Differential role for host translation factors in host and viral protein synthesis during human cytomegalovirus infection
Journal Of Virology
2014
Targeting cytomegalovirus (CMV) antigens for GBM immunotherapy
2013
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.
Proceedings of the National Academy of Sciences of the United States of America
2013
Special issue on epilepsy.
Experimental neurology
2013
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
PloS one
2013
Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.
The Journal of clinical investigation
2013
IT-017. TARGETING IDH1 MUTATIONS USING PEPTIDE VACCINES IN BRAIN TUMORS
Neuro-Oncology
2013
IT-004. A BISPECIFIC ANTIBODY REDIRECTS REGULATORY T CELLS TO KILL TUMOR CELLS THROUGH GRANZYME-DEPENDENT CYTOTOXICITY
Neuro-Oncology
2013
IT-004. A BISPECIFIC ANTIBODY REDIRECTS REGULATORY T CELLS TO KILL TUMOR CELLS THROUGH GRANZYME-DEPENDENT CYTOTOXICITY
Neuro-Oncology
2013
IMMUNOTHERAPY/BIOLOGICAL THERAPIES
Neuro-Oncology
2013
Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.
Cancer immunology research
2013
ENGINEERING RNA NANOPARTICLE VACCINES TO TARGET MALIGNANT PEDIATRIC BRAIN TUMORS: PLATFORM SESSION 413-TRAVEL STIPEND AWARD WINNER
Pediatric Blood & Cancer
2013
BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.
Cancer immunology, immunotherapy : CII
2013
Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.
Future oncology (London, England)
2013
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.
Expert review of vaccines
2013
An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.
Expert review of clinical pharmacology
2013
A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model.
Cancer immunology, immunotherapy : CII
2013
0175. A PHASE I/II STUDY OF ADOPTIVE T- CELL THERAPY (ALT) AND DC VACCINATION (DCV) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY AND HEMATOPOIETIC STEM CELL TRANSPLANTATION (HDC + ASCR) OR NON-MYELOABLATIVE CONDITIONING (NMA) IN PATIENTS (PTS) WITH RECURRENT CENTRAL PNETS (RE-MATCH PROTOCOL)
Neuro-Oncology
2013
0157. NOVEL ROLE FOR ENHANCING IMMUNOTHERAPY AGAINST PEDIATRIC BRAIN TUMORS USING HEMATOPOIETIC STEM CELLS
Neuro-Oncology
2013
0157. NOVEL ROLE FOR ENHANCING IMMUNOTHERAPY AGAINST PEDIATRIC BRAIN TUMORS USING HEMATOPOIETIC STEM CELLS
Neuro-Oncology
2013
0134. RNA NANOPARTICLE VACCINES RE-DIRECT HOST-IMMUNITY AGAINST INTRACRANIAL MALIGNANCIES
Neuro-Oncology
2013
0003. PRELIMINARY STUDY Rg3-NANOPARTICLES TREAT GLIOBLASTOMA CELLS
Neuro-Oncology
2013
TM-14. DEVELOPMENT OF IMMUNOCOMPETENT SYNGENEIC MODELS OF MEDULLOBLASTOMA FOR EVALUATION OF IMMUNOTHERAPY
Neuro-Oncology
2012
RNA NANOPARTICLE VACCINES TARGETING MEDULLOBLASTOMA:(POSTER 698)
Pediatric Blood & Cancer
2012
Monoclonal antibody therapy for malignant glioma.
Advances in experimental medicine and biology
2012
Immunotherapy of brain tumors.
Handbook of clinical neurology
2012
IT-27. ADOPTIVE CELLULAR THERAPY TARGETING RECURRENT MEDULLOBLASTOMA AND PRIMITIVE NEUROECTODERMAL TUMORS AFTER MYELOABLATIVE AND NON-MYELOABLATIVE CONDITIONING
Neuro-Oncology
2012
IT-26. FEASIBILITY OF AMPLIFIED CD133 (+) BRAIN TUMOR STEM CELL RNA-PULSED DENDRITIC CELLS FOR THE TREATMENT OF PATIENTS WITH RECURRENT GLIOBLASTOMA
Neuro-Oncology
2012
IT-20. DENDRITIC CELL VACCINES TARGETING HUMAN CYTOMEGALOVIRUS IN GLIOBLASTOMA REVEAL LYMPH NODE HOMING AS A MAJOR AXIS FOR CLINICAL INTERVENTION
Neuro-Oncology
2012
IT-20. DENDRITIC CELL VACCINES TARGETING HUMAN CYTOMEGALOVIRUS IN GLIOBLASTOMA REVEAL LYMPH NODE HOMING AS A MAJOR AXIS FOR CLINICAL INTERVENTION
Neuro-Oncology
2012
IT-09. EX VIVO GENERATION OF CENTRAL MEMORY-LIKE ANTI-TUMOR T CELLS TO TREAT MALIGNANT BRAIN TUMORS
Neuro-Oncology
2012
IR-15. ENHANCEMENT OF DENDRITIC CELL MIGRATION TO VACCINE-SITE DRAINING LYMPH NODES AS A MEANS TO GENERATE POTENT ANTI-TUMOR IMMUNE RESPONSES
Neuro-Oncology
2012
IR-13. MYELOABLATIVE TEMOZOLOMIDE INCREASES ANTIGEN-SPECIFIC CD8+ T-CELL VACCINE RESPONSES AND IS REQUIRED FOR EFFICACIOUS IMMUNOTHERAPY AGAINST INTRACEREBRAL TUMORS
Neuro-Oncology
2012
IR-09. DEVELOPING RNA NANOPARTICLE VACCINES TARGETING PEDIATRIC AND ADULT BRAIN TUMORS
Neuro-Oncology
2012
IR-08. ASSESSMENT OF INTRATUMORAL TREGS AND CLINICAL OUTCOMES IN PRIMARY AND RECURRENT GLIOBLASTOMA
Neuro-Oncology
2012
ET-49. ROLE OF HEMATOPOIETIC STEM CELLS IN ENHANCING THE ANTI-TUMOR EFFICACY OF ADOPTIVE CELLULAR THERAPY
Neuro-Oncology
2012
ET-35. TARGETING CYTOMEGALOVIRUS ANTIGENS FOR GLIOBLASTOMA IMMUNOTHERAPY
Neuro-Oncology
2012
Chasing cancer with chimeric antigen receptor therapy.
Immunotherapy
2012
A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.
PloS one
2012
Temozolamide and Radiation Therapy Does Not Cause EGFRvIII Loss
Journal Of Neurosurgery
2011
Reply to MS Lesniak
Journal of Clinical Oncology
2011
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
Blood
2011
Is cytomegalovirus a therapeutic target in glioblastoma?
Clinical cancer research : an official journal of the American Association for Cancer Research
2011
Immunotherapy for glioblastoma: The Devil Is in the Details Reply
Journal of Clinical Oncology
2011
IMMUNOLOGIC PROFILE OF PATIENTS WITH NEWLY DIAGNOSED MEDULLOBLASTOMA
Neuro-Oncology
2011
IMMUNOLOGIC PROFILE OF PATIENTS WITH NEWLY DIAGNOSED MEDULLOBLASTOMA
Neuro-Oncology
2011
IM-23. CYTOMEGALOVIRUS-SPECIFIC IMMUNE DEFICITS IN PATIENTS WITH GBM
Neuro-Oncology
2011
IM-22. DENDRITIC CELL VACCINES TARGETING CYTOMEGALOVIRUS IN GLIOBLASTOMA
Neuro-Oncology
2011
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Neuro-oncology
2011
Direct2Experts: a Pilot National Network To Demonstrate Interoperability Among Research-Networking Platforms
Journal of the American Medical Informatics Association : JAMIA
2011
Direct2Experts Collaboration Direct2Experts: a pilot national network to demonstrate interoperability among research-networking platforms
Journal of the American Medical Informatics Association
2011
Cellular Immunotherapy for Malignant Brain Tumors
2011
ADOPTIVE CELLULAR THERAPY DURING RECOVERY FROM TREATMENT-INDUCED LYMPHOPENIA IN PEDIATRIC PATIENTS WITH RECURRENT MEDULLOBLASTOMA AND PNETs
Neuro-Oncology
2011
A promising cancer vaccine
Future Oncology
2011
Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors.
Cancer immunology, immunotherapy : CII
2010
Interleukin-2 receptor α (IL-2R α/CD25)-specific antibodies eliminate regulatory T-cells (TRegs) and enhance tumor-specific immune responses
Cancer Research
2010
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010
Toward effective immunotherapy for the treatment of malignant brain tumors.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
2009
Proteomic and immunologic analyses of brain tumor exosomes.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2009
INDUCTION OF IMMUNOLOGIC AND CLINICAL RESPONSES WITH EGFRVIII-TARGETED VACCINE (CDX-110) WITH CYCLES OF TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED EGFRVIII-POSITIVE GBM
Neuro-Oncology
2009
Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM
Journal of Clinical Oncology
2009
Effect of daclizumab on TReg counts and EGFRvIII-specific immune responses in GBM
Journal of Clinical Oncology
2009
EGFRvIII-targeted vaccination therapy of malignant glioma.
Brain pathology (Zurich, Switzerland)
2009
CELLULAR IMMUNOTHERAPY TRIALS TARGETING HUMAN CYTOMEGALOVIRUS ANTIGENS IN GLIOBLASTOMA
Neuro-Oncology
2009
CELLULAR IMMUNOTHERAPY TRIALS TARGETING HUMAN CYTOMEGALOVIRUS ANTIGENS IN GLIOBLASTOMA
Neuro-Oncology
2009
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.
Molecular cancer therapeutics
2009
236. RNA Transfected Dendritic Cell Vaccines Targeting Human Cytomegalovirus Antigens in Patients with Glioblastoma
Molecular Therapy
2009
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
Seminars in immunology
2008
THE POSITIVE INFLUENCE OF TEMOZOLOMIDE ON THE HUMORAL AND CELL-MEDIATED (DTH) RESPONSES TO EGFRVIII-TARGETED VACCINE (CDX-110) IN PATIENTS WITH GBM
Neuro-Oncology
2008
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma.
Neuro-oncology
2008
Selective modification of antigen-specific T cells by RNA electroporation.
Human gene therapy
2008
Immunotherapy of malignant brain tumors.
Immunological reviews
2008
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.
Neuro-oncology
2008
Humoral and cell mediated responses to the EGFRvIII-targeted vaccine (CDX-110) are enhanced with continuous temozolomide in patients with GBM
2008
Efficacy of a phase II vaccine targeting Cytomegalovirus antigens in newly diagnosed GBM
Journal of Clinical Oncology
2008
Efficacy and immunologic effects of RNA-pulsed dendritic cell vaccines targeting human cytomegalovirus antigens in patients with glioblastoma
2008
Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM
Journal of Clinical Oncology
2008
EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells.
Cancer immunology, immunotherapy : CII
2008
Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.
Journal of immunological methods
2008
A phase I/II clinical trial evaluating RNA-loaded dendritic cells targeting human cytomegalovirus in patients with newly-diagnosed GBM
Journal of Neurosurgery
2008
Temozolomide therapy induces an increase in regulatory T-cells without abbrogating a specific tumor
Neuro-Oncology
2007
Temozolomide as a vaccine adjuvant in GBM
Journal of Clinical Oncology
2007
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.
Clinical cancer research : an official journal of the American Association for Cancer Research
2007
RNA-loaded dendritic cells targeting cytomegalovirus in patients with malignant glioma
Neuro-Oncology
2007
Induction of enhanced immunologic responses during hematopoeitic recovery from temozolomide-induced lymphopenia
Neuro-Oncology
2007
Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity.
Journal of neuroimmunology
2007
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
Clinical cancer research : an official journal of the American Association for Cancer Research
2006
Radiotherapy with regulatory T-cell depletion is synergistic for treatment of experimental model of malignant glioma
2006
Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers.
Clinical cancer research : an official journal of the American Association for Cancer Research
2006
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
Cancer research
2006
Immunotherapy for Malignant Glioma
2005
Expression profiling of CD4+ and CD8+ T cells in malignant glioma
Clinical Cancer Research
2005
Development and characterization of a novel murine brain tumor model of cytomegalovirus-associateid malignant astrocytoma
Neuro-Oncology
2004
Detection and immunologic recognition of cytomegalovirus antigens expressed within malignant gliomas
Neuro-Oncology
2004
Cytomegalovirus-specific antigens are effective targets for adoptive immunotherapy in malignant gliomas
Neuro-Oncology
2004
The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.
Journal of neuro-oncology
2003
Adoptive immunotherapy for malignant glioma.
Cancer journal (Sudbury, Mass.)
2003
Dendritic Cell Therapy
2001
RNA-transfected dendritic cells in cancer immunotherapy.
The Journal of clinical investigation
2000
Dendritic cells capture tumor derived antigens in vivo and mediate class I-restricted" cross-priming" of tumor specific cytotoxic T-cells
Journal of Investigative Dermatology
2000
Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides.
Journal of immunology (Baltimore, Md. : 1950)
1999
Direct demonstration of" cross-priming": In situ transfer of tumor antigen to dendritic cells
Journal Of Leukocyte Biology
1998
Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells.
European journal of immunology
1998
I-131 anti-CD45 antibody as a part of a conditioning regimen prior to bone marrow transplantation acute leukemia
Journal of Nuclear Medicine
1996
Molecular biology of Cryptococcus neoformans and therapy of cryptococcosis.
Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology
1994
Selection of antihypertensive therapy.
American heart journal
1990
Dosages for labetalol.
Chest
1989
